GlassScriptPhysician profile
Brian P Larsen
NPI 1083871974
$38,207.32
in general payments reported to CMS, 2019-2025
21 companies · $12K in 2025
The $12K reported for 2025 was more than what 92% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,419 · 2020: $497 · 2021: $3,395 · 2022: $7,436 · 2023: $1,055 · 2024: $7,829 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,692 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,925 · Food and Beverage: $2,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,692.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,925.34 |
| Food and Beverage | $2,843.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $14,582.99 | 2019-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $9,643.86 | 2019-2025 | Eylea Hd, Eylea |
| Regeneron Pharmaceuticals, INC. | $5,440.68 | 2021-2024 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $3,319.88 | 2023-2025 | Syfovre |
| Abbvie INC. | $2,903.78 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $591.49 | 2019-2021 | |
| Allergan, INC. | $516.15 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $361.58 | 2019-2020 | |
| Eyepoint US, INC. | $194.82 | 2021-2023 | |
| Notal Vision, INC. | $182.44 | 2022 | |
| Genentech USA, INC. | $149.49 | 2021-2023 | Vabysmo |
| Carl Zeiss Meditec USA, INC. | $120.44 | 2021 | |
| Astellas Pharma US INC | $38.03 | 2024-2025 | Izervay |
| Shire North American Group INC | $25.52 | 2019 | |
| Ani Pharmaceuticals, INC. | $24.36 | 2025 | Purified Cortrophin Gel |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $24.15 | 2023 | Xipere |
| Spark Therapeutics, INC. | $22.17 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Mallinckrodt Enterprises LLC | $18.33 | 2019 | |
| Biogen, INC. | $15.41 | 2022 | |
| Alcon Vision LLC | $12.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Larsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.